Synthesis of results Sample Clauses

Synthesis of results. The synthesis of results from the meta-analysis and systematic review are described sequentially according to each NIMH RDoC construct/subconstruct. The forest plots produced from the meta- analyses are organised per ED subgroup and subscripts denote the same study with scores for separate ED groups. A qualitative description is provided as a meta-analysis could not be performed due to low numbers of studies for the areas of ‘Reception of Non-Facial Communication’ and ‘Production of Non-Facial communication’. We did not find any articles for the area of ‘Action Perception’, which is why this subconstruct has been omitted from the results section. Two separate meta-analyses were produced for the areas of Parental Bonding: (a) care; (b) overprotection; and Self-Knowledge: (a) self-evaluation; (b) alexithymia.
Sample 1
AutoNDA by SimpleDocs
Synthesis of results. Due to the heterogeneous nature of the studies included in this review, in terms of the wide variety of dependent variables and the nature of the designs, it was not deemed possible to perform a meta-analysis on the full set of studies, and meta-analyses on a small number of sub- sets was deemed unworthy. For example, the interventions that measured actual screening uptake at 1 year follow up were heterogeneous and not comparable, with the interventions being 'computer based risk assessment' compared with a' mailed risk assessment' intervention or an 'individualised risk score' compared with a 'discussion of risk factors'. Thus, it was thought to be more appropriate to perform a narrative synthesis on all interventions. No meta- analysis was performed. Risk of Bias across Studies: No further analysis was performed to assess risk of bias as the Cochrane’s risk of bias tool was considered to be sufficient. Additional Analyses: There were no additional analyses performed in the systematic review. Results:
Sample 1
Synthesis of results. The following table refers the results in a table format, for each of the considered sequences. Table 3-1: Summary of the performance on 15 different sequences Sequence Nr. Warning event Alarm Event Owner Identification Tracking Threat Classification Success Rate 19 4 0 0 10 0 75% 20 8 8 8 5 8 83% 21 3 0 2 0 1 50% 24 2 0 2 0 0 25% 25 2 0 0 1 0 25% 26 3 3 0 2 3 42% 27 3 0 0 3 1 45% 28 4 4 1 0 4 58% 29 2 0 0 0 0 42% 32 10 9 9 3 9 83% 33 8 9 6 1 4 67% 36 4 4 0 1 4 58% Very good results, looking at the success rate are obtained in the simple sequences where there is only a person and a baggage (00-00-00-00-00). Not bad results are obtained in more complex sequences with the interference of other people and baggage (26-27-28-29-31-36-37). Not good results are obtained in relatively simple sequence with only two persons and one or two baggage (22-24-25). The success rate is more or less equal respect the previous evaluation with an improvement in complex sequence. The tracking module works better comparing it to the previous evaluation. There are improvements in the simple sequences and complex ones. The high level data fusion which leads to owner identification and threat detection is working properly, when the input data (warning and alarm events) are correctly forwarded from the lower levels of the processing chain. The final score (success rate) is computed as the rate of instances in which at least one of the processing module has issued a correct output value.
Sample 1

Related to Synthesis of results

  • Drug Test Results 1. All records pertaining to department-required drug tests shall remain confidential, and shall not be provided to other employers or agencies without the written permission of the person whose records are sought. However, medical, administrative, and immediate supervisory personnel may have access to relevant portions of the records as necessary to insure the acceptable performance of the officer's job duties.

  • Positive Test Results In the event an employee tests positive for drug use, the employee will be provided, in writing, notice of their right to explain the test results. The employee may indicate any relevant circumstance, including over the counter or prescription medication taken within the last thirty (30) days, or any other information relevant to the reliability of, or explanation for, a positive test result.

  • Test Results The employer, upon request from an employee or former employee, will provide the confidential written report issued pursuant to 4.9 of the Canadian Model in respect to that employee or former employee.

  • Publication of Results The National Aeronautics and Space Act (51 U.S.C. § 20112) requires NASA to provide for the widest practicable and appropriate dissemination of information concerning its activities and the results thereof. As such, NASA may publish unclassified and non-Proprietary Data resulting from work performed under this Agreement. The Parties will coordinate publication of results allowing a reasonable time to review and comment.

  • Evaluation Results A. Evaluation results shall be used:

  • Notification of Results Within 10 days after satisfactory inspection and/or testing of Interconnection Facilities built by the Interconnection Customer (including, if applicable, inspection and/or testing after correction of defects or failures), the Interconnected Transmission Owner shall confirm in writing to the Interconnection Customer and Transmission Provider that the successfully inspected and tested facilities are acceptable for energization.

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.

  • Treatment Program Testing The Employer may request or require an employee to undergo drug and alcohol testing if the employee has been referred by the employer for chemical dependency treatment or evaluation or is participating in a chemical dependency treatment program under an employee benefit plan, in which case the employee may be requested or required to undergo drug or alcohol testing without prior notice during the evaluation or treatment period and for a period of up to two years following completion of any prescribed chemical dependency treatment program.

  • Ownership of Results Any interest of Contractor or its subcontractors, in the Deliverables, including any drawings, plans, specifications, blueprints, studies, reports, memoranda, computation sheets, computer files and media or other documents prepared by Contractor or its subcontractors for the purposes of this Agreement, shall become the property of and will be transmitted to City. However, unless expressly prohibited elsewhere in this Agreement, Contractor may retain and use copies for reference and as documentation of its experience and capabilities.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

Time is Money Join Law Insider Premium to draft better contracts faster.